Health coverage company Centene (NYSE: CNC) announced better-than-expected revenue in Q3 CY2025, with sales up 18.2% year on year to $49.69 billion. Its non-GAAP profit of $0.50 per share was significantly above analysts’ consensus estimates.

Is now the time to buy CNC? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Centene’s third quarter results were driven by a combination of operational improvements in Medicaid and targeted risk management in its Marketplace segment. Management highlighted actions like rate advocacy—particularly in Florida—and program changes aimed at high-cost drugs, network optimization, and fraud prevention. CEO Sarah London described Medicaid performance as a key contributor, citing “fundamental improvement” due to these actions and a positive revenue adjustment in Florida. The company also noted that investment income and lower tax rates provided one-time benefits that lifted adjusted earnings above expectations.

Looking ahead, Centene’s updated guidance is shaped by a conservative posture on Medicaid profitability and plans for margin expansion in its Marketplace and Medicare Advantage businesses. Management emphasized ongoing efforts to address volatility in policy, including potential changes to advanced premium tax credits (eAPTCs) and program integrity rules. London noted, “We believe we have positioned the portfolio well for meaningful margin improvement in 2026,” while cautioning that policy developments and membership contraction remain key uncertainties. The company is preparing for multiple enrollment scenarios and investing in digital tools to support member engagement through these transitions.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to operational execution in Medicaid, targeted cost controls, and proactive engagement with state partners, while also flagging sector-specific challenges in Marketplace and Medicare.

• Medicaid rate advocacy impact: Centene’s ability to secure improved rates in Florida, including a retroactive revenue adjustment, demonstrated the effectiveness of data-driven negotiations with state partners and reinforced the importance of rate advocacy in margin recovery.
• Fraud and abuse interventions: The company emphasized aggressive interventions in New York’s behavioral health segment, including terminating high-cost providers, which led to measurable cost containment and built trust with state regulators.
• Marketplace risk management: Management responded to rising medical utilization in Marketplace by holding additional reserves and repricing products for 2026, focusing on margin over membership—especially amid uncertainty around the expiration of eAPTCs.
• Medicare segment stability: Both Medicare Advantage and Part D Prescription Drug Plan (PDP) segments performed in line with expectations, with management highlighting advances in Star ratings and risk corridor protections that provide greater margin visibility.
• SG&A discipline and investment income: Centene achieved lower selling, general and administrative (SG&A) expenses through continued cost discipline, while noting that higher-than-expected investment income in the quarter was largely one-time and not expected to recur.

Drivers of Future Performance

Centene’s outlook for the next year focuses on margin recovery initiatives in Marketplace and Medicare, balanced by a cautious approach to Medicaid profitability and ongoing policy uncertainty.

• Marketplace repricing and policy risk: Centene’s pricing for 2026 incorporates anticipated risk pool shifts, program integrity impacts, and the potential expiration of eAPTCs. Management believes these measures should drive margin expansion, but acknowledges that Congressional action on tax credits and court rulings on enrollment rules could cause volatility in membership and profitability.
• Medicaid margin stabilization: The company expects Medicaid profitability to remain consistent with 2025, citing ongoing efforts in rate advocacy, cost containment, and fraud prevention. However, management cautions that state budget pressures and regulatory changes, such as work requirements, may influence future rates and margins.
• Medicare Advantage focus on value: Centene’s strategy for Medicare prioritizes margin over membership, with product bids and network design aimed at improving profitability. Management points to recent improvements in Star ratings and risk corridor mechanisms as drivers of greater earnings stability in this segment.

Catalysts in Upcoming Quarters

In the quarters ahead, the StockStory team will closely monitor (1) the impact of Marketplace repricing and policy developments around eAPTCs on both membership and margins, (2) further evidence of cost containment and rate advocacy effectiveness in Medicaid, and (3) continued progress in Medicare Advantage Star ratings and risk adjustment mechanisms. Shifts in state and federal regulatory policy, as well as execution on digital member engagement, will also be critical markers of Centene’s performance trajectory.

Centene currently trades at $37.30, up from $33.19 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free for active Edge members).

Our Favorite Stocks Right Now

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.